New	O
complexities	O
in	O
helper	O
T	O
Cell	O
fate	O
determination	O
and	O
the	O
implications	O
for	O
autoimmune	O
diseases	O

Abstract	O

Recently	O
,	O
new	O
complexities	O
in	O
cell	O
fate	O
decision	O
for	O
helper	O
T	O
cells	O
have	O
emerged	O
.	O

One	O
new	O
lineage	O
,	O
which	O
has	O
come	O
to	O
be	O
called	O
Th17	O
cells	O
,	O
selectively	O
produces	O
proinflammatory	O
cytokines	O
including	O
interleukin-17	O
(	O
IL-17	O
,	O
A	O
and	O
F	O
)	O
,	O
IL-21	O
,	O
and	O
IL-22	O
.	O

In	O
conjunction	O
with	O
transforming	O
growth	O
factor	O
ß-1	O
(	O
TGFß-1	O
)	O
,	O
IL-6	O
,	O
IL-21	O
,	O
and	O
IL-23	O
,	O
which	O
activate	O
the	O
transcription	O
factor	O
,	O
signal	O
transducer	O
,	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
,	O
the	O
expression	O
of	O
another	O
transcription	O
factor	O
,	O
retinoic	O
acid-related	O
orphan	O
receptor-γt	O
(	O
RORγt	O
)	O
leads	O
to	O
the	O
differentiation	O
of	O
Th17	O
cells	O
in	O
mice	O
.	O

Other	O
cytokines	O
including	O
IL-2	O
,	O
IL-4	O
,	O
interferon-γ	O
(	O
IFN-γ	O
)	O
and	O
IL-27	O
inhibit	O
Th17	O
differentiation	O
.	O

However	O
,	O
IL-2	O
acting	O
with	O
TGFß-1	O
induces	O
differentiation	O
of	O
naive	O
CD4+	O
T	O
cells	O
to	O
become	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
.	O

Th17	O
cells	O
are	O
now	O
known	O
to	O
play	O
an	O
important	O
role	O
not	O
only	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
and	O
autoimmune	O
diseases	O
,	O
but	O
also	O
host	O
defense	O
against	O
extracellular	O
bacteria	O
.	O

Conversely	O
,	O
extensive	O
data	O
substantiate	O
the	O
role	O
of	O
Tregs	O
as	O
essential	O
in	O
maintenance	O
of	O
peripheral	O
tolerance	O
.	O

Selectively	C
targeting	C
Tregs	C
and	C
Th17	C
cells	C
are	C
likely	C
to	C
be	C
important	C
strategies	C
in	C
the	C
treatment	C
of	C
inflammatory	C
and	C
autoimmune	C
diseases	C
in	C
humans	C
.	C

Keywords	O
:	O
Th17	O
cells	O
,	O
autoimmune	O
diseases	O
,	O
inflammation	O
,	O
IL-17	O
,	O
Rheumatoid	O
arthritis	O

Introduction	O

It	O
is	O
well-established	O
that	O
the	O
innate	O
immune	O
response	O
leads	O
to	O
activation	O
of	O
adaptive	O
immunity	O
,	O
shaping	O
the	O
proper	O
response	O
,	O
depending	O
upon	O
the	O
pathogen	O
eliciting	O
the	O
reaction	O
.	O

Conversely	O
,	O
though	O
,	O
it	O
is	O
also	O
clear	O
that	O
adaptive	O
immune	O
response	O
,	O
especially	O
,	O
CD4+	O
or	O
helper	O
T	O
cells	O
orchestrate	O
responses	O
to	O
effectively	O
eliminate	O
pathogens	O
.	O

Classically	O
,	O
helper	O
T	O
cells	O
were	O
considered	O
to	O
differentiate	O
into	O
two	O
lineages	O
,	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
or	O
Th2	O
cells	O
(	O
1	O
)	O
.	O

In	O
addition	O
to	O
ligation	O
of	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
and	O
co-stimulatory	O
receptors	O
,	O
a	O
suitable	O
cytokine	O
milieu	O
is	O
required	O
for	O
fate	O
decision	O
of	O
helper	O
T	O
cells	O
(	O
1	O
)	O
.	O

In	O
particular	O
,	O
interleukin-12	O
(	O
IL-12	O
)	O
,	O
which	O
is	O
produced	O
by	O
activated	O
antigen-presenting	O
cells	O
(	O
APCs	O
)	O
,	O
promotes	O
Th1	O
differentiation	O
(	O
2	O
)	O
,	O
whereas	O
IL-4	O
,	O
produced	O
by	O
activated	O
T	O
cells	O
and	O
some	O
innate	O
immune	O
cells	O
,	O
drives	O
Th2	O
differentiation	O
(	O
1	O
)	O
.	O

While	O
the	O
Th1/Th2	O
paradigm	O
provided	O
invaluable	O
insights	O
for	O
immunologists	O
,	O
its	O
limitations	O
were	O
also	O
clear	O
.	O

What	O
was	O
the	O
most	O
obvious	O
was	O
the	O
inability	O
of	O
this	O
dichotomy	O
to	O
explain	O
autoimmune	O
diseases	O
.	O

More	O
recent	O
studies	O
have	O
shown	O
the	O
existence	O
of	O
the	O
additional	O
subpopulations	O
of	O
T	O
helper	O
cells	O
that	O
are	O
also	O
important	O
in	O
immunoregulation	O
and	O
host	O
defense	O
.	O

One	O
important	O
subset	O
is	O
CD4+CD25+	O
,	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
(	O
3	O
,	O
4	O
)	O
.	O

Tregs	O
suppress	O
the	O
proliferation	O
and	O
function	O
of	O
effector	O
T	O
cells	O
,	O
and	O
attenuate	O
immune	O
responses	O
against	O
self	O
or	O
nonself-antigens	O
(	O
3	O
,	O
4	O
)	O
.	O

Another	O
recently	O
identified	O
new	O
fate	O
of	O
T	O
cells	O
is	O
Th17	O
cells	O
that	O
selectively	O
produce	O
IL-17	O
(	O
A	O
and	O
F	O
)	O
(	O
5	O
,	O
6	O
)	O
.	O

In	O
the	O
past	O
three	O
years	O
,	O
discoveries	O
pertaining	O
to	O
this	O
newly	O
identified	O
T	O
helper	O
subset	O
in	O
humans	O
and	O
mice	O
have	O
accumulated	O
with	O
tremendous	O
speed	O
(	O
7-10	O
)	O
.	O

It	C
is	C
also	C
clear	C
that	C
the	C
notion	C
of	C
a	C
single	C
type	C
of	C
Th17	C
cell	C
may	C
not	C
be	C
correct	C
,	C
as	C
there	C
seems	C
to	C
be	C
further	C
complexity	C
in	C
terms	C
of	C
the	C
cytokines	C
produced	C
by	C
these	C
cells	C
.	C

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
historical	O
developments	O
that	O
led	O
to	O
a	O
new	O
understanding	O
of	O
the	O
role	O
of	O
T	O
cells	O
in	O
autoimmune	O
diseases	O
and	O
recent	O
advances	O
that	O
have	O
led	O
to	O
even	O
newer	O
insights	O
into	O
T	O
cell	O
biology	O
.	O

Pathogenicity	O
of	O
IL-23	O
,	O
but	O
not	O
IL-12	O
in	O
autoimmune	O
diseases	O

Until	C
a	C
few	C
years	C
ago	C
we	C
thought	C
we	C
knew	C
which	C
subset	C
of	C
helper	C
T	C
cells	C
was	C
responsible	C
for	C
host	C
defense	C
or	C
exacerbation	C
of	C
autoimmune	C
diseases	C
and	C
we	C
thought	C
that	C
answer	C
fit	C
well	C
with	C
the	C
standard	C
Th1/Th2	C
cells	C
paradigm	C
(	C
11	C
)	C
.	C

Th1	O
cells	O
produce	O
interferon-γ	O
(	O
IFN-γ	O
)	O
and	O
lymphotoxin	O
,	O
and	O
are	O
responsible	O
for	O
protection	O
against	O
intracellular	O
pathogens	O
such	O
as	O
viruses	O
,	O
mycobacteria	O
,	O
and	O
protozoa	O
(	O
11	O
)	O
.	O

Produced	O
by	O
activated	O
APCs	O
,	O
IL-12	O
activates	O
the	O
transcription	O
factor	O
,	O
signal	O
transducer	O
,	O
and	O
activator	O
of	O
transcription	O
4	O
(	O
Stat4	O
)	O
(	O
2	O
)	O
.	O

Stat4-dependent	O
signaling	O
in	O
conjunction	O
with	O
TCR-dependent	O
signals	O
induces	O
the	O
expression	O
of	O
T-box-expressed-in-T-cells	O
(	O
T-bet	O
)	O
,	O
the	O
so-called	O
master	O
regulator	O
of	O
Th1	O
differentiation	O
(	O
2	O
)	O
.	O

Recently	O
,	O
in	O
humans	O
,	O
it	O
has	O
been	O
shown	O
that	O
STAT4	O
polymorphisms	O
are	O
associated	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
(	O
12	O
)	O
.	O

IFN-γ	O
also	O
activates	O
Stat1	O
which	O
further	O
induces	O
T-bet	O
to	O
form	O
an	O
autocrine	O
feedback	O
loop	O
for	O
IFN-γ	O
production	O
(	O
2	O
)	O
.	O

T-bet	O
promotes	O
not	O
only	O
IFN-γ	O
production	O
but	O
also	O
suppression	O
of	O
Th2	O
cytokines	O
production	O
by	O
T	O
cells	O
(	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Th2	O
cells	O
produce	O
IL-4	O
,	O
IL-5	O
,	O
and	O
IL-13	O
(	O
1	O
)	O
.	O

IL-4	O
activates	O
Stat6	O
,	O
which	O
up-regulates	O
the	O
expression	O
of	O
GATA-binding	O
protein	O
3	O
(	O
GATA-3	O
)	O
(	O
1	O
)	O
.	O

Th2	O
cytokines	O
are	O
potent	O
activators	O
of	O
B-cell	O
Immunoglobulin	O
E	O
production	O
,	O
eosinophil	O
recruitment	O
,	O
and	O
mucosal	O
expulsion	O
mechanisms	O
,	O
and	O
are	O
essential	O
for	O
promoting	O
host	O
defense	O
against	O
helminths	O
and	O
other	O
parasites	O
(	O
1	O
)	O
.	O

In	O
addition	O
,	O
Th2	O
cells	O
have	O
been	O
shown	O
to	O
mediate	O
allergic	O
diseases	O
such	O
as	O
asthma	O
,	O
rhinitis	O
,	O
and	O
atopic	O
dermatitis	O
(	O
11	O
)	O
.	O

Traditionally	C
,	C
autoimmune	C
diseases	C
had	C
been	C
assumed	C
to	C
be	C
associated	C
with	C
dysregulated	C
Th1	C
responses	C
(	C
13	C
)	C
.	C

Because	C
the	C
treatment	C
with	C
anti-IL-12p40	C
antibody	C
was	C
effective	C
in	C
Crohn	C
's	C
disease	C
(	C
CD	C
)	C
and	C
psoriasis	C
(	C
14	C
,	C
15	C
)	C
,	C
it	C
was	C
further	C
assumed	C
that	C
IL-12-mediated	C
IFN-γ	C
production	C
and	C
Th1	C
response	C
were	C
involved	C
in	C
the	C
pathogenesis	C
of	C
autoimmunity	C
.	C

However	O
,	O
it	O
was	O
shown	O
that	O
IFN-γ	O
deficiency	O
exacerbated	O
rather	O
than	O
ameliorated	O
mouse	O
models	O
of	O
autoimmune	O
diseases	O
such	O
as	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
(	O
16	O
)	O
.	O

Subsequently	O
,	O
a	O
new	O
cytokine	O
,	O
which	O
consists	O
of	O
IL-23p19	O
and	O
IL-12p40	O
,	O
was	O
identified	O
and	O
termed	O
IL-23	O
(	O
17	O
)	O
.	O

Interestingly	O
,	O
the	O
IL-23	O
receptor	O
(	O
IL-23R	O
)	O
forms	O
dimers	O
with	O
the	O
IL-12Rß1	O
chain	O
shared	O
by	O
IL-12	O
and	O
IL-23	O
(	O
18	O
)	O
.	O

IL-23R	O
is	O
predominantly	O
expressed	O
on	O
T	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
(	O
18	O
,	O
19	O
)	O
.	O

IL-23	O
activates	O
Janus	O
kinase	O
2	O
(	O
Jak2	O
)	O
and	O
tyrosine	O
kinase	O
2	O
(	O
Tyk2	O
)	O
,	O
which	O
in	O
turn	O
leads	O
to	O
activation	O
of	O
Stat1	O
,	O
Stat3	O
,	O
Stat4	O
,	O
and	O
Stat5	O
,	O
among	O
which	O
Stat3	O
is	O
the	O
predominant	O
factor	O
phosphorylated	O
by	O
this	O
cytokine	O
(	O
17	O
,	O
18	O
)	O
.	O

Of	O
note	O
,	O
IL-23p19-deficient	O
mice	O
or	O
IL-12p40-deficient	O
(	O
IL-12/IL-23-deficient	O
)	O
mice	O
were	O
resistant	O
to	O
collagen-induced	O
arthritis	O
(	O
CIA	O
)	O
and	O
EAE	O
(	O
20	O
,	O
21	O
)	O
.	O

However	O
,	O
IL-12p35-deficient	O
mice	O
had	O
increased	O
susceptibility	O
to	O
CIA	O
and	O
EAE	O
(	O
20	O
,	O
21	O
)	O
.	O

These	O
studies	O
directly	O
negated	O
the	O
pathogenic	O
role	O
of	O
the	O
IL-12/IFN-γ	O
axis	O
in	O
autoimmunity	O
.	O

This	O
was	O
an	O
important	O
piece	O
of	O
information	O
that	O
led	O
to	O
the	O
unraveling	O
of	O
the	O
Th1/Th2	O
paradigm	O
as	O
an	O
explanation	O
of	O
autoimmunity	O
.	O

Accordingly	O
,	O
additional	O
studies	O
on	O
IL-23p19-deficient	O
mice	O
and	O
the	O
anti-IL-23p19	O
antibody	O
revealed	O
that	O
IL-23	O
,	O
but	O
not	O
IL-12	O
,	O
was	O
the	O
culprit	O
in	O
autoimmunity	O
,	O
at	O
least	O
in	O
mouse	O
disease	O
models	O
(	O
21-23	O
)	O
.	O

The	O
pathogenic	O
role	O
of	O
IL-23	O
was	O
also	O
confirmed	O
by	O
the	O
phenotype	O
of	O
IL-23p19	O
transgenic	O
mice	O
,	O
in	O
which	O
premature	O
death	O
,	O
systemic	O
inflammation	O
,	O
anemia	O
,	O
and	O
elevated	O
serum	O
levels	O
of	O
inflammatory	O
cytokines	O
and	O
acute	O
phase	O
proteins	O
were	O
observed	O
(	O
22	O
)	O
.	O

In	C
human	C
disease	C
,	C
the	C
mRNA	C
levels	C
of	C
both	C
IL-23p19	C
and	C
IL-12p40	C
were	C
shown	C
to	C
be	C
increased	C
in	C
skin	C
lesions	C
of	C
psoriatic	C
patients	C
(	C
24	C
)	C
,	C
suggesting	C
that	C
elevated	C
IL-23	C
contributed	C
to	C
the	C
pathogenesis	C
of	C
psoriasis	C
.	C

Therefore	O
,	O
IL-23	O
began	O
to	O
attract	O
attention	O
as	O
a	O
factor	O
crucial	O
to	O
inflammation	O
and	O
autoimmune	O
diseases	O
.	O

The	O
IL-23/IL17	O
axis	O
in	O
inflammation	O

While	O
it	O
was	O
becoming	O
clear	O
that	O
IL-23	O
was	O
the	O
culprit	O
in	O
autoimmune	O
and	O
inflammatory	O
diseases	O
,	O
the	O
question	O
remained	O
,	O
how	O
was	O
it	O
acting	O
?	O

Another	O
inflammatory	O
cytokine	O
,	O
IL-17	O
,	O
was	O
noted	O
to	O
be	O
produced	O
by	O
activated	O
purified	O
T	O
cells	O
in	O
the	O
presence	O
of	O
LPS-stimulated	O
dendritic	O
cells	O
(	O
DCs	O
)	O
(	O
5	O
)	O
.	O

It	O
was	O
also	O
found	O
that	O
IL-23	O
promoted	O
IL-17	O
production	O
from	O
memory	O
T	O
cells	O
and	O
this	O
production	O
was	O
suppressed	O
by	O
treatment	O
with	O
anti-IL-12p40	O
antibody	O
(	O
5	O
)	O
.	O

Now	O
IL-17	O
is	O
recognized	O
as	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
proinflammatory	O
cytokines	O
:	O
IL-17	O
(	O
IL-17A	O
)	O
,	O
IL-17B	O
,	O
IL-17C	O
,	O
IL-17D	O
,	O
IL-17E	O
(	O
known	O
as	O
IL-25	O
)	O
,	O
and	O
IL-17F	O
(	O
6	O
)	O
.	O

IL-17A	O
and	O
IL-17F	O
induce	O
the	O
production	O
of	O
various	O
proinflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor-α	O
(	O
TNF-	O
α	O
)	O
,	O
IL-1ß	O
,	O
and	O
IL-6	O
,	O
and	O
CXC	O
chemokines	O
from	O
monocytes	O
,	O
airway	O
epithelial	O
cells	O
,	O
vein	O
endothelial	O
cells	O
,	O
and	O
fibroblasts	O
to	O
mount	O
defense	O
against	O
extracellular	O
bacteria	O
such	O
as	O
Klebsiella	O
pneumonia	O
,	O
Bacteroides	O
fragilis	O
,	O
and	O
Mycobacterium	O
tuberculosis	O
(	O
6	O
,	O
25	O
,	O
26	O
)	O
.	O

These	O
responses	O
result	O
in	O
the	O
recruitment	O
,	O
activation	O
and	O
migration	O
of	O
neutrophils	O
to	O
the	O
sites	O
of	O
inflammation	O
and	O
infection	O
(	O
6	O
)	O
.	O

CD4+	O
T	O
cells	O
are	O
major	O
producers	O
of	O
IL-17	O
,	O
but	O
in	O
addition	O
CD8+	O
T	O
cells	O
,	O
neutrophils	O
,	O
γδ	O
T	O
cells	O
,	O
and	O
invariant	O
natural	O
killer	O
T	O
(	O
NKT	O
)	O
cells	O
also	O
produce	O
this	O
cytokine	O
(	O
26-28	O
)	O
.	O

Various	O
reports	O
associated	O
IL-23	O
with	O
IL-17	O
production	O
with	O
the	O
onset	O
or	O
exacerbation	O
of	O
inflammation	O
(	O
20-23	O
,	O
29	O
)	O
.	O

For	O
instance	O
,	O
IL-23p19-deficient	O
mice	O
showed	O
reduced	O
incidence	O
of	O
CIA	O
,	O
with	O
fewer	O
IL-17-producing	O
CD4+	O
T	O
cells	O
(	O
20	O
)	O
.	O

Consistent	O
with	O
this	O
report	O
,	O
treatment	O
with	O
anti-IL-23p19	O
antibody	O
reduced	O
serum	O
levels	O
of	O
IL-17	O
and	O
inhibited	O
development	O
of	O
EAE	O
(	O
29	O
)	O
.	O

Moreover	O
,	O
IL-23	O
was	O
found	O
to	O
be	O
essential	O
for	O
production	O
of	O
IL-17	O
and	O
IL-6	O
in	O
colitis	O
mouse	O
models	O
(	O
22	O
,	O
23	O
)	O
.	O

Regardless	O
of	O
exactly	O
how	O
IL-23	O
works	O
,	O
these	O
reports	O
supported	O
the	O
idea	O
that	O
an	O
IL-23/IL-17	O
axis	O
,	O
but	O
not	O
IL-12/IFN-γ	O
axis	O
,	O
was	O
a	O
crucial	O
pathway	O
in	O
the	O
pathogenesis	O
of	O
various	O
autoimmune	O
diseases	O
(	O
21	O
,	O
30	O
)	O
.	O

Regulation	O
of	O
Th17	O
differentiation	O

Although	O
many	O
results	O
linked	O
IL-23	O
with	O
IL-17	O
production	O
in	O
CD4+	O
T	O
cells	O
,	O
less	O
was	O
known	O
about	O
how	O
Th17	O
cells	O
arose	O
from	O
naive	O
CD4+	O
T	O
cells	O
.	O

It	C
was	C
very	C
clear	C
that	C
development	C
of	C
IL-17-producing	C
T	C
cells	C
was	C
not	C
dependent	C
on	C
the	C
cytokines	C
and	C
the	C
transcription	C
factors	C
required	C
for	C
Th1	C
or	C
Th2	C
differentiation	C
and	C
then	C
it	C
was	C
proposed	C
that	C
IL-17-producing	C
CD4+	C
T	C
cells	C
represented	C
a	C
new	C
subset	C
of	C
helper	C
T	C
cells	C
(	C
Th17	C
cells	C
)	C
,	C
which	C
were	C
crucial	C
in	C
mediating	C
inflammatory	C
responses	C
(	C
30-32	C
)	C
.	C

While	C
there	C
was	C
evidence	C
that	C
IL-23	C
stimulated	C
CD4+	C
T	C
cells	C
to	C
express	C
various	C
genes	C
,	C
including	C
IL-17	C
,	C
and	C
that	C
IL-23-stimulated	C
T	C
cells	C
were	C
important	C
in	C
the	C
pathogenesis	C
of	C
EAE	C
(	C
30	C
)	C
,	C
it	C
was	C
less	C
clear	C
whether	C
IL-23	C
was	C
the	C
factor	C
that	C
drove	C
naive	C
CD4+	C
T	C
cells	C
to	C
become	C
IL-17	C
producers	C
.	C

It	O
was	O
especially	O
puzzling	O
that	O
naive	O
CD4+	O
T	O
cells	O
did	O
not	O
express	O
IL-23R	O
(	O
18	O
)	O
.	O

In	O
a	O
search	O
for	O
optinum	O
culture	O
condition	O
for	O
Th17	O
differentiation	O
it	O
was	O
recognized	O
that	O
naive	O
CD4+	O
T	O
cells	O
cultured	O
with	O
activated	O
DCs	O
produced	O
IL-17	O
(	O
16	O
)	O
.	O

It	O
was	O
then	O
recognized	O
that	O
the	O
combination	O
of	O
IL-6	O
and	O
transforming	O
growth	O
factor	O
ß-1	O
(	O
TGFß-1	O
)	O
,	O
with	O
appropriate	O
stimulation	O
of	O
TCR	O
,	O
were	O
the	O
optinum	O
stimuli	O
inducing	O
Th17	O
differentiation	O
(	O
Fig	O
.	O
1a	O
)	O
(	O
16	O
)	O
.	O

Accordingly	O
,	O
TGFß-1-deficient	O
mice	O
showed	O
impaired	O
Th17	O
development	O
,	O
whereas	O
addition	O
of	O
TGFß-1	O
rescued	O
the	O
number	O
of	O
Th17	O
cells	O
(	O
7	O
,	O
33	O
)	O
.	O

Thus	O
it	O
became	O
clear	O
that	O
IL-23	O
was	O
not	O
the	O
direct	O
initiator	O
of	O
Th17	O
production	O
(	O
16	O
)	O
,	O
but	O
rather	O
was	O
an	O
important	O
factor	O
for	O
expanding	O
and	O
maintaining	O
Th17	O
cells	O
in	O
vivo	O
(	O
34	O
)	O
.	O

New	O
T	O
cell	O
lineages	O
in	O
mice	O
(	O
a	O
)	O
and	O
humans	O
(	O
c	O
)	O
.	O

When	O
stimulated	O
by	O
APCs	O
such	O
as	O
DCs	O
and	O
macrophages	O
,	O
and	O
cognate	O
peptide	O
,	O
naive	O
helper	O
T	O
cells	O
differentiate	O
into	O
lineages	O
determined	O
by	O
the	O
cytokine	O
milieu	O
.	O

TGFß-1	O
is	O
a	O
critical	O
factor	O
in	O
the	O
differentiation	O
of	O
new	O
two	O
lineages	O
in	O
mice	O
T	O
cells	O
.	O

In	O
conjunction	O
with	O
TCR	O
stimulation	O
,	O
the	O
combination	O
of	O
TGFß-1	O
and	O
IL-2	O
(	O
and	O
other	O
γc	O
cytokines	O
)	O
induces	O
the	O
expression	O
of	O
Foxp3	O
,	O
leading	O
to	O
the	O
differentiation	O
of	O
naive	O
CD4+	O
T	O
cells	O
into	O
anti-inflammatory	O
Tregs	O
(	O
a	O
)	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
TGFß-1	O
with	O
IL-6	O
or	O
IL-21	O
,	O
which	O
activates	O
Stat3	O
and	O
up-regulates	O
RORγt	O
,	O
naive	O
CD4+	O
T	O
cells	O
develop	O
to	O
become	O
pro-inflammatory	O
Th17	O
cells	O
(	O
a	O
)	O
.	O

Th17	O
differentiation	O
is	O
suppressed	O
by	O
IFN-γ	O
,	O
IL-4	O
,	O
IL-2	O
,	O
IL-25	O
,	O
IL-27	O
,	O
and	O
retinoic	O
acid	O
in	O
mice	O
(	O
b	O
)	O
.	O

Both	O
Th17	O
cells	O
and	O
Tregs	O
are	O
also	O
present	O
in	O
humans	O
(	O
c	O
)	O
.	O

TGFß-1	O
,	O
IL-1ß	O
,	O
and	O
IL-2	O
in	O
combination	O
with	O
IL-6	O
,	O
IL-21	O
or	O
IL-23	O
are	O
necessary	O
for	O
human	O
Th17	O
differentiation	O
(	O
c	O
)	O
.	O

APCs	O
,	O
antigen-presenting	O
cells	O
;	O
iTregs	O
,	O
inducible	O
Tregs	O

Autocrine	O
regulation	O
of	O
Th17	O
differentiation	O
by	O
IL-21	O

In	O
the	O
classic	O
Th1/Th2	O
paradigm	O
,	O
T	O
cell	O
subsets	O
produce	O
factors	O
that	O
promote	O
their	O
differentiation	O
and	O
constrain	O
the	O
differentiation	O
of	O
the	O
opposing	O
lineage	O
.	O

It	O
was	O
of	O
interest	O
in	O
this	O
regard	O
that	O
the	O
Th17	O
cells	O
were	O
found	O
to	O
selectively	O
produce	O
IL-21	O
(	O
35-38	O
)	O
.	O

IL-21	O
has	O
structural	O
homology	O
with	O
IL-2	O
and	O
IL-15	O
,	O
and	O
the	O
initial	O
report	O
showed	O
the	O
effects	O
of	O
IL-21	O
produced	O
by	O
CD4+	O
T	O
cells	O
and	O
NKT	O
cells	O
on	O
the	O
proliferation	O
and	O
function	O
of	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
and	O
T	O
cells	O
(	O
39	O
,	O
40	O
)	O
.	O

Recently	O
though	O
,	O
it	O
has	O
also	O
been	O
found	O
that	O
the	O
autocrine	O
production	O
of	O
IL-21	O
by	O
Th17	O
cells	O
promotes	O
Th17	O
differentiation	O
while	O
inhibiting	O
IFN-γ	O
production	O
(	O
35-38	O
)	O
.	O

Accordingly	O
,	O
the	O
deficiency	O
of	O
IL-21	O
(	O
or	O
its	O
receptor	O
)	O
,	O
or	O
blocking	O
of	O
IL-21	O
,	O
attenuates	O
the	O
generation	O
of	O
Th17	O
cells	O
(	O
35-37	O
)	O
.	O

Transcription	O
factors	O
for	O
Th17	O
differentiation	O

To	O
precisely	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
Th17	O
differentiation	O
,	O
it	O
is	O
important	O
to	O
define	O
the	O
transcription	O
factors	O
that	O
directly	O
regulate	O
IL-17	O
production	O
.	O

All	O
of	O
IL-6	O
,	O
IL-21	O
,	O
and	O
IL-23	O
activate	O
the	O
transcription	O
factor	O
Stat3	O
in	O
T	O
cells	O
(	O
38	O
,	O
41	O
,	O
42	O
)	O
;	O
accordingly	O
,	O
Th17	O
differentiation	O
is	O
abrogated	O
in	O
Stat3-deficient	O
T	O
cells	O
(	O
38	O
,	O
42-45	O
)	O
.	O

Moreover	O
,	O
conditional	O
deletion	O
of	O
Stat3	O
in	O
T	O
cells	O
also	O
abrogates	O
the	O
development	O
of	O
autoimmune	O
diseases	O
such	O
as	O
EAE	O
and	O
autoimmune	O
pneumonitis	O
in	O
mice	O
(	O
43	O
)	O
.	O

The	C
role	C
of	C
Stat3	C
in	C
Th17	C
differentiation	C
seems	C
to	C
be	C
remarkably	C
direct	C
–	C
i.e	C
.	C
Stat3	C
binds	C
to	C
the	C
Il17	C
and	C
Il21	C
loci	C
,	C
as	C
detected	C
by	C
using	C
chromatin	C
immunoprecipitation	C
(	C
ChiP	C
)	C
assays	C
(	C
38	C
,	C
41	C
)	C
.	C

In	O
addition	O
,	O
IL-6	O
and	O
IL-23	O
promote	O
IL-23R	O
expression	O
and	O
this	O
also	O
is	O
Stat3-dependent	O
(	O
10	O
,	O
36	O
,	O
37	O
)	O
.	O

Recently	O
,	O
the	O
importance	O
of	O
Stat3	O
in	O
human	O
Th17	O
differentiation	O
has	O
been	O
documented	O
(	O
46	O
)	O
.	O

Like	O
other	O
T	O
cell	O
subsets	O
,	O
Th17	O
cells	O
also	O
have	O
a	O
lineage-specific	O
transcription	O
factor	O
,	O
namely	O
the	O
retinoic	O
acid-related	O
orphan	O
receptor-γt	O
(	O
RORγt	O
)	O
(	O
8	O
)	O
.	O

Interestingly	O
,	O
RORγt-deficient	O
T	O
cells	O
produce	O
fewer	O
Th17	O
cells	O
,	O
whereas	O
overexpression	O
of	O
RORγt	O
in	O
T	O
cells	O
promotes	O
IL-17	O
expression	O
(	O
8	O
)	O
.	O

Furthermore	C
,	C
RORγt-deficient	C
mice	C
are	C
less	C
susceptible	C
to	C
EAE	C
,	C
suggesting	C
that	C
RORγt	C
is	C
a	C
key	C
regulator	C
of	C
Th17	C
differentiation	C
(	C
8	C
)	C
.	C

Recent	O
studies	O
have	O
shown	O
that	O
RORγt	O
expression	O
is	O
significantly	O
reduced	O
in	O
Stat3-deficient	O
T	O
cells	O
(	O
43-45	O
)	O
.	O

However	C
,	C
the	C
precise	C
molecular	C
mechanisms	C
of	C
Stat3-mediated	C
expression	C
of	C
RORγt	C
are	C
still	C
unclear	C
.	C

Even	C
so	C
,	C
RORγt	C
could	C
be	C
a	C
good	C
candidate	C
to	C
target	C
in	C
treating	C
inflammatory	C
diseases	C
(	C
discussed	C
in	C
further	C
detail	C
below	C
)	C
.	C

Also	O
,	O
it	O
has	O
been	O
shown	O
that	O
expression	O
of	O
another	O
retinoic	O
acid	O
related	O
nuclear	O
receptor	O
,	O
RORα	O
also	O
induces	O
Th17	O
differentiation	O
(	O
47	O
)	O
.	O

RORα	C
seems	C
to	C
synergize	C
with	C
RORγt	C
to	C
promote	C
development	C
of	C
Th17	C
lineage	C
(	C
47	C
)	C
.	C

Counter-regulation	O
of	O
IL-17	O
and	O
the	O
Yin/Yang	O
of	O
Th17	O
cells	O
and	O
Tregs	O

Because	C
of	C
their	C
potential	C
for	C
inducing	C
immune-mediated	C
damage	C
to	C
the	C
host	C
,	C
it	C
is	C
perhaps	C
not	C
surprising	C
that	C
multiple	C
mechanisms	C
exist	C
to	C
inhibit	C
the	C
production	C
of	C
Th17	C
cells	C
(	C
Fig	C
.	C
1b	C
)	C
.	C

Indeed	O
,	O
it	O
has	O
been	O
recognized	O
that	O
the	O
Th1-related	O
cytokine	O
IFN-γ	O
inhibits	O
Th17	O
differentiation	O
(	O
31	O
,	O
32	O
)	O
.	O

Consistent	O
with	O
this	O
concept	O
,	O
T-bet-deficient	O
mice	O
show	O
enhanced	O
Th17	O
differentiation	O
(	O
48	O
)	O
.	O

Similarly	O
,	O
the	O
Th2-related	O
IL-4	O
is	O
also	O
shown	O
to	O
down-regulate	O
Th17	O
differentiation	O
(	O
49	O
)	O
.	O

However	C
,	C
how	C
IFN-γ	C
and	C
IL-4	C
inhibit	C
IL-17	C
production	C
is	C
not	C
yet	C
known	C
.	C

Interestingly	O
,	O
IL-27	O
,	O
an	O
IL-12-related	O
heterodimeric	O
cytokine	O
,	O
also	O
has	O
anti-inflammatory	O
effect	O
by	O
inhibiting	O
the	O
generation	O
of	O
Th17	O
lineage	O
and	O
leads	O
to	O
limitation	O
of	O
EAE	O
(	O
50	O
)	O
.	O

Like	O
IFN-γ	O
,	O
IL-27	O
suppresses	O
Th17	O
differentiation	O
through	O
a	O
STAT1-dependent	O
manner	O
(	O
51	O
,	O
52	O
)	O
.	O

IL-25	O
(	O
IL-17E	O
)	O
was	O
also	O
shown	O
to	O
inhibit	O
IL-17	O
production	O
by	O
promoting	O
Th2	O
differentiation	O
(	O
53	O
)	O
.	O

These	C
reports	C
suggest	C
a	C
cross-regulatory	C
relationship	C
among	C
Th1	C
,	C
Th2	C
,	C
and	C
Th17	C
differentiation	C
.	C

However	C
,	C
it	C
still	C
remains	C
to	C
be	C
determined	C
how	C
Th1-related	C
and	C
Th2-related	C
transcription	C
factors	C
negatively	C
regulate	C
IL-17	C
production	C
.	C

Another	O
new	O
subset	O
of	O
helper	O
T	O
cells	O
that	O
provides	O
considerable	O
insight	O
into	O
the	O
pathogenesis	O
of	O
autoimmunity	O
is	O
the	O
CD4+CD25+	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
(	O
3	O
,	O
4	O
,	O
54	O
)	O
.	O

Tregs	O
suppress	O
proliferation	O
of	O
effector	O
T	O
cells	O
and	O
maintain	O
self	O
tolerance	O
by	O
down-regulating	O
immune	O
responses	O
against	O
self	O
or	O
nonself-antigens	O
(	O
3	O
,	O
4	O
,	O
54	O
)	O
.	O

The	C
mechanism	C
by	C
which	C
Tregs	C
preserve	C
peripheral	C
tolerance	C
is	C
still	C
not	C
entirely	C
clear	C
;	C
however	C
,	C
they	C
preferentially	C
express	C
cytotoxic	C
T-lymphocyte	C
antigen	C
4	C
(	C
CTLA-4	C
)	C
,	C
and	C
immunosuppressive	C
cytokines	C
including	C
TGFß-1	C
and	C
IL-10	C
(	C
55-57	C
)	C
.	C

Naturally	O
arising	O
Tregs	O
(	O
nTregs	O
)	O
are	O
generated	O
in	O
the	O
thymus	O
,	O
whereas	O
inducible	O
Tregs	O
(	O
iTregs	O
)	O
arise	O
from	O
naive	O
T	O
cells	O
after	O
antigen	O
exposure	O
and	O
cytokine	O
stimulation	O
in	O
the	O
periphery	O
,	O
especially	O
in	O
the	O
gut	O
(	O
58	O
)	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
CD4+CD25+	O
T	O
cells	O
express	O
the	O
transcription	O
factor	O
,	O
forkhead	O
box	O
protein	O
3	O
(	O
Foxp3	O
)	O
,	O
which	O
is	O
necessary	O
and	O
sufficient	O
for	O
Tregs	O
to	O
develop	O
and	O
function	O
(	O
59	O
,	O
60	O
)	O
.	O

In	O
mice	O
,	O
IL-2	O
and	O
TGFß-1	O
were	O
able	O
to	O
differentiate	O
CD4+CD25-	O
naive	O
T	O
cells	O
into	O
CD4+	O
CD25+	O
Foxp3+	O
Tregs	O
(	O
61	O
,	O
62	O
)	O
.	O

Therefore	O
,	O
the	O
importance	O
of	O
TGFß-1	O
for	O
both	O
Tregs	O
and	O
Th17	O
lineage	O
led	O
to	O
the	O
speculation	O
that	O
these	O
lineages	O
were	O
related	O
.	O

This	C
putative	C
relationship	C
also	C
led	C
to	C
investigation	C
of	C
the	C
importance	C
of	C
IL-2	C
in	C
Th17	C
differentiation	C
(	C
44	C
)	C
.	C

In	O
fact	O
,	O
IL-2	O
was	O
found	O
to	O
inhibit	O
the	O
expression	O
of	O
RORγt	O
while	O
the	O
enhancing	O
expression	O
of	O
Foxp3	O
(	O
44	O
)	O
.	O

Furthermore	C
,	C
blockade	C
of	C
IL-2	C
or	C
deletion	C
of	C
Stat5	C
promoted	C
Th17	C
differentiation	C
,	C
suggesting	C
that	C
IL-2	C
inhibited	C
Th17	C
lineage	C
by	C
affecting	C
the	C
RORγt-Foxp3	C
balance	C
(	C
44	C
)	C
.	C

Therefore	C
,	C
helper	C
T	C
cells	C
seem	C
to	C
have	C
a	C
unique	C
way	C
of	C
achieving	C
a	C
balance	C
between	C
Tregs	C
and	C
Th17	C
cells	C
during	C
ongoing	C
immune	C
responses	C
.	C

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
TGFß-1	O
can	O
promote	O
either	O
Th17	O
or	O
Tregs	O
lineage	O
differentiation	O
,	O
depending	O
on	O
its	O
local	O
concentration	O
(	O
63	O
)	O
.	O

Interestingly	C
,	C
Foxp3	C
may	C
inhibit	C
RORγt	C
activity	C
on	C
its	C
target	C
genes	C
,	C
at	C
least	C
in	C
par	C
,	C
t	C
through	C
direct	C
interaction	C
with	C
RORγt	C
(	C
63	C
)	C
.	C

Further	O
complexities	O
of	O
Th17	O
cells	O

The	O
roles	O
of	O
Th17	O
cells	O
are	O
complicated	O
by	O
the	O
fact	O
that	O
these	O
cells	O
also	O
have	O
the	O
ability	O
to	O
produce	O
anti-inflammatory	O
cytokines	O
such	O
as	O
IL-10	O
(	O
34	O
)	O
.	O

This	O
cytokine	O
has	O
anti-inflammatory	O
properties	O
that	O
suppress	O
functions	O
of	O
DCs	O
and	O
macrophages	O
(	O
64	O
)	O
.	O

IL-10	O
can	O
be	O
produced	O
by	O
many	O
cell	O
types	O
such	O
as	O
B	O
cells	O
,	O
macrophages	O
,	O
DCs	O
,	O
Th2	O
cells	O
,	O
and	O
distinct	O
populations	O
of	O
Tregs	O
(	O
64	O
)	O
.	O

Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
de-novo	O
generation	O
of	O
Th17	O
cells	O
in	O
the	O
presence	O
of	O
IL-6	O
and	O
TGFß-1	O
leads	O
to	O
the	O
production	O
of	O
IL-10	O
with	O
up-regulation	O
of	O
RORγt	O
and	O
IL-17	O
(	O
34	O
)	O
.	O

Furthermore	O
,	O
IL-1ß	O
,	O
but	O
not	O
IL-23	O
,	O
potentiates	O
IL-10	O
production	O
in	O
Th17	O
cells	O
along	O
with	O
IL-6	O
and	O
TGFß-1	O
(	O
34	O
)	O
.	O

Paradoxically	C
,	C
IL-6	C
and	C
TGFß-1	C
seem	C
to	C
drive	C
initial	C
Th17	C
lineage	C
commitment	C
but	C
also	C
restrain	C
the	C
pathogenic	C
potential	C
of	C
Th17	C
cells	C
by	C
producing	C
IL-10	C
also	C
(	C
34	C
)	C
.	C

Another	O
cytokine	O
produced	O
by	O
Th17	O
cells	O
is	O
IL-22	O
(	O
25	O
,	O
65	O
,	O
66	O
)	O
.	O

IL-22	O
belongs	O
to	O
the	O
IL-10	O
family	O
of	O
cytokines	O
which	O
include	O
IL-19	O
,	O
IL-20	O
,	O
IL-24	O
,	O
and	O
IL-26	O
.	O

Expressed	O
in	O
activated	O
T	O
cells	O
,	O
Th1	O
cells	O
and	O
NK	O
cells	O
(	O
67	O
)	O
,	O
IL-22	O
induces	O
expression	O
of	O
various	O
antimicrobial	O
peptides	O
such	O
as	O
ß-defensins	O
in	O
skin	O
,	O
respiratory	O
,	O
and	O
digestive	O
tissues	O
,	O
which	O
express	O
IL-22R	O
(	O
68	O
)	O
.	O

In	O
fact	O
,	O
expression	O
of	O
IL-22	O
and	O
ß-defensins	O
is	O
higher	O
in	O
skin	O
from	O
patients	O
with	O
psoriasis	O
and	O
atopic	O
dermatitis	O
than	O
in	O
that	O
from	O
healthy	O
individuals	O
(	O
69	O
)	O
.	O

While	O
it	O
is	O
clear	O
that	O
IL-22	O
and	O
IL-17	O
can	O
contribute	O
to	O
host	O
defense	O
and	O
to	O
pathogenesis	O
of	O
various	O
autoimmune	O
diseases	O
(	O
25	O
)	O
,	O
it	O
is	O
also	O
notable	O
that	O
IL-22	O
also	O
has	O
important	O
anti-inflammatory	O
effects	O
(	O
70	O
)	O
.	O

Specifically	O
,	O
IL-22-expressing	O
Th17	O
cells	O
provided	O
protection	O
in	O
models	O
of	O
hepatitis	O
(	O
70	O
)	O
.	O

Recently	O
,	O
IL-22	O
also	O
has	O
been	O
shown	O
not	O
to	O
be	O
required	O
for	O
the	O
development	O
of	O
EAE	O
in	O
mice	O
(	O
71	O
)	O
.	O

These	O
facts	O
indicate	O
the	O
complexity	O
of	O
Th17	O
cells	O
,	O
which	O
produce	O
multiple	O
cytokines	O
and	O
have	O
diverse	O
functions	O
during	O
inflammation	O
.	O

As	C
such	C
,	C
their	C
relevance	C
may	C
vary	C
among	C
different	C
autoimmune	C
diseases	C
.	C

Human	O
Th17	O
differentiation	O

While	O
a	O
large	O
body	O
of	O
evidence	O
has	O
documented	O
that	O
the	O
best	O
recipe	O
for	O
generating	O
Th17	O
cells	O
from	O
murine	O
naive	O
CD4+	O
T	O
cells	O
is	O
the	O
combination	O
of	O
TGFß-1	O
and	O
IL-6	O
or	O
IL-21	O
,	O
several	O
groups	O
initially	O
reported	O
that	O
the	O
regulation	O
of	O
human	O
Th17	O
differentiation	O
was	O
quite	O
distinct	O
(	O
Fig	O
.	O
1c	O
)	O
(	O
9	O
,	O
10	O
,	O
66	O
,	O
72-74	O
)	O
.	O

Specifically	O
,	O
TGFß-1	O
was	O
initially	O
considered	O
to	O
have	O
inhibitory	O
effect	O
on	O
human	O
IL-17	O
production	O
;	O
however	O
,	O
the	O
role	O
of	O
TGFß-1	O
in	O
human	O
Th17	O
differentiation	O
has	O
recently	O
become	O
clearer	O
.	O

While	O
TGFß-1	O
alone	O
had	O
an	O
inhibitory	O
effect	O
on	O
production	O
of	O
IL-17	O
by	O
T	O
cells	O
,	O
culturing	O
human	O
naive	O
CD4+	O
T	O
cells	O
from	O
cord	O
blood	O
in	O
serum-free	O
medium	O
revealed	O
a	O
requirement	O
of	O
TGFß-1	O
for	O
Th17	O
differentiation	O
(	O
72	O
)	O
.	O

TGFß-1	C
seems	C
to	C
have	C
dual	C
effects	C
on	C
human	C
Th17	C
differentiation	C
in	C
a	C
dose-dependent	C
manner	C
.	C

While	O
TGFß-1	O
is	O
required	O
for	O
the	O
expression	O
of	O
RORγt	O
in	O
human	O
naive	O
CD4+	O
T	O
cells	O
from	O
cord	O
blood	O
,	O
TGFß-1	O
can	O
inhibit	O
the	O
function	O
of	O
RORγt	O
at	O
high	O
doses	O
(	O
72	O
)	O
.	O

However	O
,	O
inflammatory	O
cytokines	O
(	O
IL-1ß	O
,	O
IL-6	O
,	O
and	O
IL-21	O
or	O
IL-23	O
)	O
relieve	O
the	O
latter	O
effect	O
of	O
TGFß-1	O
(	O
72	O
)	O
.	O

By	O
using	O
serum-free	O
medium	O
it	O
has	O
thus	O
been	O
clarified	O
that	O
the	O
optimum	O
conditions	O
for	O
human	O
Th17	O
differentiation	O
are	O
TGFß-1	O
,	O
IL-1ß	O
,	O
and	O
IL-2	O
in	O
combination	O
with	O
IL-6	O
,	O
IL-21	O
or	O
IL-23	O
(	O
72-74	O
)	O
.	O

Of	C
these	C
latter	C
cytokines	C
,	C
IL-23	C
seems	C
to	C
be	C
the	C
most	C
effective	C
(	C
10	C
,	C
66	C
,	C
72	C
,	C
73	C
)	C
.	C

A	O
key	O
aspect	O
of	O
Th17	O
regulation	O
is	O
the	O
regulation	O
of	O
IL-23R	O
(	O
10	O
)	O
.	O

Naive	O
CD4+	O
T	O
cells	O
express	O
low	O
levels	O
of	O
this	O
receptor	O
,	O
but	O
the	O
combination	O
of	O
TGFß-1	O
,	O
IL-1ß	O
,	O
and	O
IL-23	O
can	O
strongly	O
induce	O
this	O
receptor	O
(	O
10	O
,	O
72	O
)	O
.	O

Thus	O
,	O
IL-23	O
promotes	O
expression	O
of	O
its	O
own	O
receptor	O
,	O
allowing	O
it	O
to	O
be	O
an	O
effective	O
inducer	O
of	O
IL-17	O
.	O

It	O
is	O
of	O
note	O
is	O
that	O
CCR6+IL-23R+	O
human	O
memory	O
CD4+	O
T	O
cells	O
are	O
major	O
producers	O
of	O
IL-17	O
(	O
75	O
,	O
76	O
)	O
.	O

Because	C
CCR6+CD4+	C
T	C
cells	C
,	C
but	C
not	C
CCR6-CD4+	C
T	C
cells	C
,	C
secrete	C
IL-17	C
and	C
expression	C
of	C
IL-23R	C
,	C
CCR6	C
,	C
and	C
RORγt	C
is	C
up-regulated	C
during	C
Th17	C
differentiation	C
(	C
72	C
)	C
,	C
these	C
factors	C
seem	C
to	C
be	C
essential	C
for	C
development	C
of	C
human	C
Th17	C
lineage	C
.	C

Importantly	C
,	C
it	C
has	C
been	C
shown	C
that	C
mutations	C
presumed	C
to	C
underlie	C
hyper-IgE	C
syndrome	C
(	C
HIES	C
,	C
“Job	C
's	C
syndrome”	C
)	C
are	C
identified	C
in	C
the	C
STAT3	C
gene	C
(	C
46	C
)	C
.	C

Purified	C
naive	C
CD4+	C
T	C
cells	C
from	C
HIES	C
individuals	C
can	C
not	C
differentiate	C
into	C
Th17	C
cells	C
in	C
vitro	C
and	C
have	C
lower	C
expression	C
of	C
RORγt	C
(	C
46	C
)	C
,	C
suggesting	C
that	C
Stat3	C
signaling	C
is	C
also	C
a	C
crucial	C
factor	C
for	C
the	C
generation	C
of	C
human	C
Th17	C
cells	C
.	C

Th17	O
cells	O
in	O
autoimmune	O
diseases	O

Although	C
Th17	C
cells	C
are	C
important	C
and	C
essential	C
subsets	C
participating	C
in	C
host	C
defense	C
against	C
extracellular	C
antigens	C
,	C
evidence	C
implicating	C
Th17	C
cells	C
as	C
a	C
causal	C
factor	C
of	C
autoimmune	C
diseases	C
is	C
also	C
mounting	C
(	C
25	C
)	C
.	C

Following	O
extensive	O
analysis	O
of	O
mouse	O
disease	O
models	O
such	O
as	O
EAE	O
,	O
CIA	O
,	O
and	O
IBD	O
,	O
it	O
has	O
also	O
become	O
evident	O
that	O
IL-17	O
is	O
a	O
contributing	O
factor	O
in	O
human	O
autoimmune	O
diseases	O
.	O

For	O
instance	O
,	O
perivascular	O
IL-17-producing	O
T	O
cells	O
are	O
present	O
in	O
brain	O
lesions	O
of	O
active	O
MS	O
patients	O
and	O
these	O
cells	O
are	O
reduced	O
in	O
quiescent	O
MS	O
patients	O
(	O
77	O
)	O
.	O

Moreover	O
,	O
DCs	O
from	O
MS	O
patients	O
secrete	O
more	O
IL-23	O
than	O
healthy	O
controls	O
,	O
and	O
T	O
cells	O
from	O
MS	O
patients	O
secrete	O
more	O
IL-17	O
than	O
healthy	O
controls	O
(	O
78	O
)	O
.	O

Also	O
,	O
elevated	O
levels	O
of	O
IL-17	O
have	O
been	O
noted	O
in	O
the	O
sera	O
and	O
in	O
tissues	O
of	O
patients	O
with	O
RA	O
,	O
IBD	O
,	O
and	O
psoriasis	O
(	O
25	O
)	O
.	O

We	O
will	O
see	O
more	O
evidence	O
confirming	O
the	O
roles	O
of	O
IL-17	O
in	O
human	O
diseases	O
and	O
inflammation	O
in	O
the	O
future	O
.	O

Recent	O
genetic	O
data	O
has	O
linked	O
polymorphisms	O
of	O
the	O
Il23r	O
gene	O
to	O
various	O
human	O
diseases	O
such	O
as	O
ankylosing	O
spondylitis	O
,	O
CD	O
,	O
and	O
psoriasis	O
(	O
79-81	O
)	O
.	O

Accordingly	O
treating	O
CD	O
and	O
psoriasis	O
patients	O
with	O
anti-IL-12p40	O
antibody	O
has	O
resulted	O
in	O
some	O
success	O
(	O
14	O
,	O
15	O
)	O
.	O

These	C
results	C
argue	C
strongly	C
for	C
a	C
role	C
of	C
the	C
IL-23/IL-17	C
axis	C
in	C
human	C
autoimmune	C
diseases	C
.	C

Th17	O
cells	O
in	O
rheumatoid	O
arthritis	O

It	C
is	C
of	C
particular	C
interest	C
to	C
evaluate	C
the	C
contribution	C
of	C
Th17	C
cells	C
to	C
the	C
pathogenesis	C
of	C
RA	C
,	C
because	C
targeting	C
pathogenetic	C
Th17	C
might	C
be	C
a	C
reasonable	C
strategy	C
for	C
treating	C
RA	C
.	C

First	O
,	O
IL-17-deficient	O
mice	O
fail	O
to	O
develop	O
CIA	O
when	O
challenged	O
(	O
82	O
)	O
.	O

Consistent	O
with	O
this	O
,	O
treatment	O
with	O
neutralizing	O
IL-17	O
monoclonal	O
antibody	O
ameliorates	O
joint	O
inflammation	O
in	O
CIA	O
models	O
(	O
83	O
)	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
reported	O
that	O
active	O
immunization	O
using	O
virus-like	O
particles	O
conjugated	O
with	O
recombinant	O
IL-17	O
leads	O
to	O
high	O
levels	O
of	O
anti-IL-17	O
antibodies	O
in	O
mice	O
and	O
reduces	O
scores	O
of	O
disease	O
severity	O
in	O
CIA	O
(	O
84	O
)	O
.	O

These	O
results	O
highlight	O
the	O
role	O
of	O
IL-17	O
as	O
an	O
exacerbation	O
factor	O
in	O
rodent	O
arthritis	O
models	O
.	O

Because	C
the	C
expression	C
of	C
IL-17	C
and	C
IL-23p19	C
was	C
observed	C
in	C
the	C
synovial	C
fluid	C
and	C
serum	C
of	C
RA	C
patients	C
,	C
these	C
factors	C
were	C
presumed	C
to	C
be	C
pathogenic	C
(	C
85	C
)	C
.	C

In	O
particular	O
,	O
IL-17	O
up-regulates	O
the	O
production	O
of	O
IL-1ß	O
and	O
TNF-α	O
from	O
APCs	O
in	O
arthritic	O
joints	O
(	O
86	O
,	O
87	O
)	O
.	O

Moreover	O
,	O
IL-17	O
induces	O
IL-6	O
,	O
IL-8	O
,	O
and	O
IL-23	O
from	O
RA	O
synovial	O
fibroblasts	O
and	O
chemokines	O
such	O
as	O
CCL20/MIP3α	O
from	O
synoviocytes	O
to	O
induce	O
migration	O
of	O
T	O
cells	O
and	O
DCs	O
into	O
inflammatory	O
lesions	O
(	O
86	O
,	O
87	O
)	O
.	O

IL-17	O
also	O
promotes	O
cartilage	O
breakdown	O
by	O
inducing	O
matrix	O
metalloproteinases-1	O
(	O
MMP-1	O
)	O
from	O
RA	O
synovium	O
(	O
86	O
,	O
87	O
)	O
.	O

Additionally	O
,	O
IL-17	O
induces	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
-dependent	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
synthesis	O
by	O
osteoblasts	O
and	O
it	O
then	O
induces	O
expression	O
of	O
receptor	O
activator	O
of	O
NF-κB	O
ligand	O
(	O
RANKL	O
)	O
to	O
differentiate	O
osteoclast	O
progenitors	O
into	O
mature	O
osteoclasts	O
(	O
86	O
,	O
87	O
)	O
.	O

Pro-oxidants	O
such	O
as	O
nitric	O
oxide	O
are	O
also	O
produced	O
by	O
chondrocytes	O
and	O
osteoblasts	O
in	O
response	O
to	O
IL-17	O
(	O
86	O
,	O
87	O
)	O
.	O

Taken	C
together	C
,	C
these	C
multiple	C
factors	C
induced	C
by	C
IL-17	C
seem	C
to	C
promote	C
bone	C
resorption	C
,	C
extracellular	C
matrix	C
degradation	C
,	C
synovium	C
proliferation	C
,	C
angiogenesis	C
,	C
and	C
recruitment	C
and	C
activation	C
of	C
immune	C
cells	C
for	C
bone	C
erosion	C
and	C
articular	C
destruction	C
in	C
RA	C
joints	C
.	C

This	C
being	C
said	C
,	C
there	C
is	C
little	C
evidence	C
of	C
T	C
cell	C
proliferation	C
in	C
RA	C
and	C
we	C
still	C
do	C
not	C
know	C
for	C
certain	C
the	C
cellular	C
source	C
of	C
IL-17	C
in	C
RA	C
synovium	C
(	C
88	C
)	C
.	C

For	C
these	C
reasons	C
,	C
IL-17	C
seems	C
to	C
be	C
a	C
rational	C
target	C
in	C
the	C
treatment	C
of	C
RA	C
,	C
and	C
Phase	C
I/II	C
clinical	C
trials	C
of	C
anti-IL-17	C
monoclonal	C
antibody	C
(	C
AIN457	C
)	C
have	C
commenced	C
(	C
http	C
:	C
//www.clinicaltrials.gov/	C
)	C
.	C

It	O
has	O
been	O
reported	O
that	O
combining	O
inhibitors	O
to	O
block	O
TNF-α	O
and	O
IL-17	O
has	O
the	O
synergistic	O
effect	O
of	O
suppressing	O
IL-6	O
production	O
and	O
collagen	O
degradation	O
in	O
the	O
synovium	O
and	O
bone	O
of	O
RA	O
patients	O
(	O
89	O
)	O
.	O

Therefore	C
,	C
anti-IL-17	C
therapy	C
may	C
become	C
an	C
alternative	C
for	C
treating	C
patients	C
unresponsive	C
to	C
conventional	C
anti-TNF	C
therapy	C
.	C

It	C
still	C
remains	C
to	C
be	C
seen	C
whether	C
blocking	C
IL-17	C
will	C
affect	C
other	C
proinflammatory	C
cytokines	C
for	C
example	C
IL-6	C
,	C
IL-1	C
,	C
and	C
IL-22	C
in	C
RA	C
patients	C
.	C

More	O
studies	O
will	O
shed	O
light	O
on	O
the	O
validity	O
of	O
anti-IL-17	O
therapy	O
.	O

While	O
the	O
role	O
of	O
IL-6	O
in	O
regulating	O
IL-17	O
production	O
has	O
only	O
recently	O
been	O
appreciated	O
,	O
the	O
role	O
of	O
IL-6	O
as	O
a	O
proinflammatory	O
cytokine	O
has	O
long	O
been	O
recognized	O
.	O

For	O
this	O
reason	O
,	O
targeting	O
IL-6	O
in	O
RA	O
has	O
been	O
considered	O
for	O
some	O
time	O
.	O

Indeed	O
the	O
efficacy	O
of	O
humanized	O
anti	O
IL-6R	O
monoclonal	O
antibodies	O
(	O
tocilizumab/atlizumab	O
)	O
in	O
the	O
treatment	O
of	O
adults	O
and	O
children	O
with	O
arthritis	O
has	O
recently	O
been	O
reported	O
(	O
90	O
)	O
.	O

Also	O
,	O
in	O
April	O
2008	O
tocilizumab	O
was	O
been	O
approved	O
in	O
Japan	O
for	O
treatment	O
of	O
RA	O
in	O
Japan	O
,	O
and	O
Phase	O
III	O
trials	O
have	O
been	O
completed	O
in	O
the	O
US	O
(	O
http	O
:	O
//www.clinicaltrials.gov/	O
)	O
.	O

To	C
what	C
extent	C
their	C
efficacy	C
relates	C
to	C
inhibition	C
of	C
IL-17	C
will	C
be	C
important	C
to	C
ascertain	C
.	C

Similarly	O
,	O
in	O
the	O
US	O
,	O
recombinant	O
human	O
anti-IL-1Rα	O
antagonist	O
(	O
anakinra	O
)	O
has	O
been	O
approved	O
for	O
use	O
in	O
the	O
treatment	O
of	O
RA	O
(	O
91	O
)	O
.	O

Recently	O
,	O
more	O
IL-1-targeting	O
therapies	O
for	O
RA	O
patients	O
are	O
in	O
Phase	O
II	O
studies	O
including	O
anti-IL-1ß	O
monoclonal	O
antibody	O
(	O
ACZ885	O
)	O
,	O
human	O
monoclonal	O
antibody	O
to	O
IL-1R	O
(	O
AMG108	O
)	O
,	O
and	O
IL-1	O
Trap/rilonacept	O
(	O
http	O
:	O
//www.clinicaltrials.gov/	O
)	O
.	O

Although	C
IL-1	C
has	C
been	C
reported	C
to	C
contribute	C
to	C
Th17	C
differentiation	C
in	C
mouse	C
and	C
man	C
,	C
it	C
remains	C
to	C
be	C
determined	C
whether	C
therapeutic	C
targeting	C
of	C
IL-1	C
will	C
substantially	C
affect	C
IL-17	C
in	C
RA	C
.	C

On	O
the	O
basis	O
of	O
the	O
efficacy	O
of	O
anti-IL-12p40	O
therapy	O
in	O
human	O
autoimmune	O
diseases	O
(	O
14	O
,	O
15	O
)	O
,	O
a	O
humanized	O
monoclonal	O
anti-IL-12p40	O
antibody	O
(	O
ABT-874	O
)	O
was	O
tested	O
in	O
RA	O
(	O
92	O
)	O
.	O

However	O
this	O
antibody	O
was	O
not	O
shown	O
to	O
be	O
effective	O
because	O
of	O
the	O
trial	O
design	O
(	O
92	O
)	O
.	O

Another	O
strategy	O
for	O
targeting	O
IL-12/IL-23	O
is	O
apilimod	O
mesylate	O
(	O
STA-5326	O
)	O
,	O
an	O
oral	O
inhibitor	O
of	O
IL-12p35/p40	O
,	O
which	O
has	O
been	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
for	O
RA	O
(	O
http	O
:	O
//www.clinicaltrials.gov/	O
)	O
.	O

Whether	C
selectively	C
targeting	C
IL-23p19	C
will	C
be	C
more	C
efficacious	C
or	C
have	C
a	C
better	C
safety	C
profile	C
remains	C
to	C
be	C
determined	C
.	C

In	C
principle	C
,	C
targeting	C
IL-21	C
might	C
also	C
be	C
efficacious	C
in	C
treating	C
RA	C
in	C
which	C
IL-17	C
is	C
involved	C
in	C
immune-mediated	C
damage	C
.	C

Importantly	O
,	O
the	O
common	O
gamma	O
chain	O
and	O
JAK3	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
IL-21	O
(	O
25	O
)	O
.	O

In	O
fact	O
,	O
a	O
JAK3	O
inhibitor	O
(	O
CP-690550	O
)	O
is	O
about	O
to	O
be	O
tested	O
in	O
RA	O
(	O
Phase	O
II	O
trial	O
)	O
(	O
http	O
:	O
//www.clinicaltrials.gov/	O
)	O
.	O

It	C
will	C
be	C
important	C
to	C
know	C
whether	C
the	C
efficacy	C
of	C
this	C
drug	C
is	C
related	C
to	C
inhibition	C
of	C
IL-17	C
.	C

Concluding	O
remarks	O

The	O
past	O
four	O
years	O
have	O
witnessed	O
major	O
revisions	O
of	O
our	O
views	O
on	O
the	O
lineage	O
commitment	O
of	O
helper	O
T	O
cells	O
.	O

The	O
conventional	O
Th1/Th2	O
dichotomy	O
has	O
been	O
replaced	O
by	O
more	O
complex	O
multi-lineage	O
models	O
which	O
do	O
a	O
much	O
better	O
job	O
of	O
explaining	O
the	O
pathogenesis	O
of	O
autoimmunity	O
(	O
Fig	O
.	O
1	O
)	O
.	O

It	C
now	C
seems	C
that	C
Th17	C
cells	C
are	C
one	C
of	C
the	C
more	C
important	C
villains	C
in	C
the	C
pathogenesis	C
of	C
autoimmune	C
diseases	C
.	C

However	O
,	O
it	O
is	O
of	O
note	O
that	O
they	O
are	O
also	O
essential	O
for	O
host	O
defense	O
against	O
extracellular	O
bacteria	O
.	O

Therefore	O
,	O
the	O
challenge	O
will	O
be	O
to	O
keep	O
Th17	O
function	O
in	O
check	O
to	O
control	O
autoimmunity	O
,	O
while	O
maintaining	O
host	O
defense	O
at	O
the	O
same	O
time	O
.	O

In	O
this	O
regard	O
,	O
we	O
still	O
need	O
to	O
learn	O
what	O
are	O
the	O
most	O
critical	O
factors	O
for	O
Th17	O
differentiation	O
.	O

We	O
also	O
need	O
to	O
better	O
understand	O
which	O
human	O
autoimmune	O
diseases	O
are	O
truly	O
mediated	O
by	O
IL-17	O
and	O
,	O
by	O
extension	O
,	O
which	O
diseases	O
will	O
benefit	O
most	O
from	O
anti-IL-17	O
therapy	O
.	O

With	O
the	O
current	O
pace	O
of	O
investigations	O
on	O
Th17	O
,	O
this	O
field	O
has	O
a	O
great	O
potential	O
for	O
advances	O
.	O

There	C
is	C
no	C
doubt	C
that	C
IL-17	C
and	C
the	C
other	C
proinflammatory	C
cytokines	C
are	C
likely	C
to	C
be	C
relevant	C
therapeutic	C
targets	C
in	C
the	C
treatment	C
of	C
human	C
autoimmune	C
diseases	C
.	C

Estrogen	O
directly	O
activates	O
AID	O
transcription	O
and	O
function	O

Abstract	O

The	O
immunological	O
targets	O
of	O
estrogen	O
at	O
the	O
molecular	O
,	O
humoral	O
,	O
and	O
cellular	O
level	O
have	O
been	O
well	O
documented	O
,	O
as	O
has	O
estrogen	O
's	O
role	O
in	O
establishing	O
a	O
gender	O
bias	O
in	O
autoimmunity	O
and	O
cancer	O
.	O

During	O
a	O
healthy	O
immune	O
response	O
,	O
activation-induced	O
deaminase	O
(	O
AID	O
)	O
deaminates	O
cytosines	O
at	O
immunoglobulin	O
(	O
Ig	O
)	O
loci	O
,	O
initiating	O
somatic	O
hypermutation	O
(	O
SHM	O
)	O
and	O
class	O
switch	O
recombination	O
(	O
CSR	O
)	O
.	O

Protein	C
levels	C
of	C
nuclear	C
AID	C
are	C
tightly	C
controlled	C
,	C
as	C
unregulated	C
expression	C
can	C
lead	C
to	C
alterations	C
in	C
the	C
immune	C
response	C
.	C

Furthermore	O
,	O
hyperactivation	O
of	O
AID	O
outside	O
the	O
immune	O
system	O
leads	O
to	O
oncogenesis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
estrogen–estrogen	O
receptor	O
complex	O
binds	O
to	O
the	O
AID	O
promoter	O
,	O
enhancing	O
AID	O
messenger	O
RNA	O
expression	O
,	O
leading	O
to	O
a	O
direct	O
increase	O
in	O
AID	O
protein	O
production	O
and	O
alterations	O
in	O
SHM	O
and	O
CSR	O
at	O
the	O
Ig	O
locus	O
.	O

Enhanced	O
translocations	O
of	O
the	O
c-myc	O
oncogene	O
showed	O
that	O
the	O
genotoxicity	O
of	O
estrogen	O
via	O
AID	O
production	O
was	O
not	O
limited	O
to	O
the	O
Ig	O
locus	O
.	O

Outside	O
of	O
the	O
immune	O
system	O
(	O
e.g.	O
,	O
breast	O
and	O
ovaries	O
)	O
,	O
estrogen	O
induced	O
AID	O
expression	O
by	O
>	O
20-fold	O
.	O

The	O
estrogen	O
response	O
was	O
also	O
partially	O
conserved	O
within	O
the	O
DNA	O
deaminase	O
family	O
(	O
APOBEC3B	O
,	O
-3F	O
,	O
and	O
-3G	O
)	O
,	O
and	O
could	O
be	O
inhibited	O
by	O
tamoxifen	O
,	O
an	O
estrogen	O
antagonist	O
.	O

We	C
therefore	C
suggest	C
that	C
estrogen-induced	C
autoimmunity	C
and	C
oncogenesis	C
may	C
be	C
derived	C
through	C
AID-dependent	C
DNA	C
instability	C
.	C

